Ruvonoflast clinical trials
Also written NT-0796.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses ruvonoflast is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NT-0796
- 3
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Rezera (formerly NodThera Limited) (3)
Studies
Open first, then newest update. How each study uses ruvonoflast is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Effects of NT-0796 in Obese Participants at Risk of Cardiovascular DiseaseCompletedPhase 1Rezera (formerly NodThera Limited)NCT06129409Written as NT-0796
- Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)CompletedPhase 2Rezera (formerly NodThera Limited)NCT07220629Written as NT-0796
- Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes MellitusCompletedPhase 2Rezera (formerly NodThera Limited)NCT07055516Written as NT-0796
Codes
What other systems call ruvonoflast · ClinicalTrials.gg INT017867
- UNII (FDA) S7V5RX5WBZRUVONOFLASTConfirmed FDA, Wikidata
- Wikidata Q140529320ruvonoflastConfirmed FDA, Wikidata
- NCI Thesaurus C223303RuvonoflastOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S7V5RX5WBZ | RUVONOFLAST | Confirmed FDA, Wikidata |
| Wikidata | Q140529320 | ruvonoflast | Confirmed FDA, Wikidata |
| NCI Thesaurus | C223303 | Ruvonoflast | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.